Henshaw Capital’s Takeda Pharmaceutical TAK Stock Holding History

Henshaw Capital’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-30,391	Closed	-$542K	–	352
2020 Q3	$542K	Hold	30,391	–	–	0.04%	144
2020 Q2	$545K	Hold	30,391	–	–	0.05%	138
2020 Q1	$461K	Buy	30,391 +4,839	+19%	+$87.7K	0.05%	143
2019 Q4	$504K	Hold	25,552	–	–	0.04%	144
2019 Q3	$439K	Buy	25,552 +791	+3%	+$13.7K	0.04%	154
2019 Q2	$438K	Buy	24,761 +6,111	+33%	+$111K	0.04%	155
2019 Q1	$380K	Hold	18,650	–	–	0.03%	175
2018 Q4	$314K	Buy	+18,650	New	+$315K	0.03%	182

Other funds holding TAK

GCM

Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

PPA

Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Henshaw Capital's TAK Position: Q4 2020 in Review

Henshaw Capital sold out of Takeda Pharmaceutical (TAK) in Q4 2020, closing a stake of 30,391 shares — an estimated $542K sold.

Henshaw Capital first reported a position in TAK in Q4 2018 and held it in 8 quarters. The position peaked at $545K in Q2 2020. 313 funds tracked by Wall St. Rank hold TAK as of Q4 2020.

Henshaw Capital reported no remaining Takeda Pharmaceutical position as of Q4 2020 after selling out during the quarter.
Henshaw Capital sold 30,391 Takeda Pharmaceutical shares in Q4 2020, an estimated $542K.
Henshaw Capital first reported a position in Takeda Pharmaceutical in Q4 2018 and held it in 8 quarters.
Henshaw Capital's Takeda Pharmaceutical position peaked at $545K in Q2 2020.
313 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2020.

Based on Henshaw Capital's 13F filing for Q4 2020, filed 28 May 2026.